DETERMINATION OF CYP2D6 PHENOTYPING FOR METOPROLOL USING THE CYP2D6 GENOTYPE-DERIVED ACTIVITY SCORE: RESULTS FROM A PROSPECTIVE, CLINICAL TRIAL.

被引：0
|
作者：
Thomas, C. D. [1 ]
Mosley, S. A. [1 ]
El Rouby, N. [1 ]
Kim, S. [2 ]
Lingineni, K. [2 ]
Langaee, T. [1 ]
Gong, Y. [1 ]
Johnson, J. A. [1 ]
Schmidt, S. O. [1 ]
Schmidt, S. [2 ]
Frye, R. F. [1 ]
Cavallari, L. H. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Univ Florida, Orlando, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
LB-028
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Human liver CYP2D6 genotype, full-length mRNA, and activity, assessed with a novel CYP2D6 substrate
    Bodor, M
    McConnachie, L
    Kowdley, K
    Levy, A
    Tun, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DD
    Ho, RJY
    DRUG METABOLISM REVIEWS, 2004, 36 : 113 - 113
  • [32] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [33] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [34] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
  • [35] The activity score (AS):: Facilitating CYP2D6 phenotype prediction from genotype data.
    Gaedigk, A.
    Simon, S. D.
    Pearce, R. E.
    Kennedy, M. J.
    Bradford, L. D.
    Leeder, J. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S85 - S86
  • [36] Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism
    Dorado, Pedro
    Gonzalez, Idilio
    Naranjo, Maria Eugenia G.
    de Andres, Fernando
    Penas-Lledo, Eva Maria
    Calzadilla, Luis Ramon
    LLerena, Adrian
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2017, 21 (01) : 17 - 26
  • [37] The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
    Gaedigk, A.
    Simon, S. D.
    Pearce, R. E.
    Bradford, L. D.
    Kennedy, M. J.
    Leeder, J. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 234 - 242
  • [38] Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
    Hamelin, BA
    Bouayad, A
    Méthot, J
    Jobin, J
    Desgagnés, P
    Poirier, P
    Allaire, J
    Dumesnil, J
    Turgeon, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (05) : 466 - 477
  • [39] Analysis of CYP2D6 genotype and response to tetrabenazine
    Mehanna, Raja
    Hunter, Christine
    Davidson, Anthony
    Jimenez-Shahed, Joohi
    Jankovic, Joseph
    MOVEMENT DISORDERS, 2013, 28 (02) : 210 - 215
  • [40] Correlation of CYP2D6 genotype with response to tetrabenazine
    Mehanna, R.
    Hunter, C.
    Davidson, A.
    Jimenez-Shahed, J.
    Ondo, W.
    Jankovic, J.
    MOVEMENT DISORDERS, 2012, 27 : S457 - S457
12345